Quick Answer
Viridian Therapeutics, Inc.DE reported R&D Expense of $34.79 million for fiscal year 2019.
Viridian Therapeutics, Inc.DE R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2019 | $34.79M | +14.4% |
| 2018 | $30.42M | +55.0% |
| 2017 | $19.62M | +43.3% |
| 2016 | $13.69M | +1266.5% |
| 2015 | $1.00M | +188.8% |
| 2014 | $347.0K | +54.2% |
| 2013 | $225.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2020 | $3.11M | -65.5% | -18.9% |
| June 30, 2020 | $3.84M | -55.4% | -37.1% |
| March 31, 2020 | $6.10M | -30.3% | -32.4% |
| September 30, 2019 | $9.03M | +22.0% | +5.0% |
| June 30, 2019 | $8.60M | +2.7% | -1.7% |
| March 31, 2019 | $8.75M | +36.5% | +18.3% |
| September 30, 2018 | $7.40M | +47.4% | -11.7% |
| June 30, 2018 | $8.38M | +52.6% | +30.6% |
- Viridian Therapeutics, Inc.DE showed an increase of +14.4% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2019 period, Viridian Therapeutics, Inc.DE’s r&d expense has grown by 15364.0% (from $225.0 thousand to $34.79 million).
- The most recent figure is from Viridian Therapeutics, Inc.DE’s fiscal year 2019 report (Form 10-K), filed with the SEC on March 13, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: